– AB126 is an unmodified exosome derived from neural stem cells with the innate ability to cross the blood-brain-barrier and provide potential therapeutic benefit for multiple neurological indications –
BOSTON and ATHENS, Ga., Aug. 15, 2023 (GLOBE NEWSWIRE) — Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced an oral presentation at the Exosome Based Therapeutic Development Summit, being held in Boston, MA from September 5-7, 2023 as well as the Applications of Exosomes as part of the BioProcess International Conference & Exhibition, being held in Boston from September 18-21, 2023. Proof-of-concept data from lead program, AB126 will be featured in two podium presentations highlighting the treatment opportunities of neural exosomes. AB126 is an unmodified neural-derived exosome with the innate ability to cross the blood-brain barrier and provide potential therapeutic benefit in its native form for multiple neurological indications.
Conference and presentation details are as follows:
Exosome Based Therapeutic Development Summit
Applications of Exosomes BioProcess International Conference & Exhibition
About Aruna Bio
Aruna Bio is a leader in the development of neural exosomes for the treatment of neurodegenerative diseases. The company is utilizing its proprietary neural exosome platform and manufacturing capability to develop a pipeline of neural exosome-based therapeutics able to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders where significant unmet medical need exists today. Additionally, the company’s neural exosome platform can be combined with therapeutics, such as small molecules, siRNAs and proteins, to cross the blood brain barrier and to the site of disease.
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…
Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field AblationCARDIFF-BY-THE-SEA, Calif., Feb. 5,…
SAN JOSE, Calif., Feb. 5, 2026 /PRNewswire/ -- LEADOPTIK, Inc., a medical technology company focused…
Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…
KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…
While AI booms, Berry delivers quiet confidence to parents by pairing each child's unique logged…